FDA Approves Merck’s KEYTRUDA (pembrolizumab) as Adjuvant Treatment for Adult and Pediatric (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection Read more
Merck Announces Pause in Enrollment for Two Phase 3 Clinical Trials of Investigational, Once-Monthly, Oral Islatravir for Pre-Exposure Prophylaxis (PrEP) of HIV-1 infection Read more
Quantum Genomics Signs an Exclusive License and Production Agreement with Gulf Pharmaceuticals Industries Julphar Read more
Jacobio Receives IND Approval for Combination Therapy of KRAS G12C and Cetuximab Injection in China Read more
Resilience Acquires SwiftScale Biologics, a Leader in Cell-Free Protein Synthesis Technology Read more
MHRA grants conditional marketing authorisation1 for COVID-19 treatment Xevudy (sotrovimab) Read more